Priapism - a possible side-effect of olanzapine by Elizabeta Dadić-Hero et al.







Priapism – a possible side-effect of olanzapine 
 
Prijapizam – moguća nuspojava olanzapina 
 




The evaluation of the effects of antipsychotics on sexual function in patients with schizophrenia is complex 
because it is difficult to discern whether a particular dysfunction is a consequence of the disease itself or it is 
a side effect of a particular medication. One of such dysfunctions is priapism. We will present a case of a 
patient who has been in treatment for schizophrenia for the last 26 years. As extrapyramidal side effects have  
occurred over the past two years, the first generation antipsychotics were replaced with olanzapine. At the 
same time the patient was involved in a multidisciplinary psychosocial treatment program consisting of 
psychoeducation, social skills training and therapeutic community. After three months of group treatment, he 
mentioned painful penile erection. Olanzapine was reduced and risperidone introduced by gradual titration (4 
mg daily). Four weeks after having administered risperdone, the painful erection subsided completely. This 
case illustrated the importance of psychosocial interventions, especially psychoeducation, in timely 
recognition and reporting all symptoms/side effects. Also, in cases of possible antipsychotic-induced priapism, 
a medication with less alpha-1 antagonism should be considered and used at the lowest effective dose.  




Procjena učinaka antipsihotika na spolnu funkciju bolesnika sa shizofrenijom je složena, pogotovo stoga 
jer je teško razlučiti je li određena disfunkcija posljedica same bolesti ili je nuspojava određenoga lijeka. Jedna 
od takvih disfunkcija je prijapizam. Predstavit ćemo slučaj bolesnika koji se posljednjih 26 godina liječi od 
shizofrenije. Kako su se tijekom posljednje dvije godine pojavile ekstrapiramidalne nuspojave, prva generacija 
antipsihotika zamijenjena je olanzapinom. Istodobno je bolesnik bio uključen u multidisciplinarni 
psihosocijalni program koji se sastojao od psihoedukacije, treninga socijalnih vještina i terapijske zajednice. 
Nakon tri mjeseca grupnog tretmana spomenuo je problem s bolnom erekcijom penisa. Olanzapin je smanjen, 
a risperidon uveden postupnom titracijom (4 mg dnevno). Četiri tjedna nakon uvođenja risperdona, bolna 
erekcija se potpuno povukla. Ovaj slučaj ilustrirao je važnost psihosocijalnih intervencija, posebno 
psihoedukacije, u pravodobnom prepoznavanju i prijavljivanju svih simptoma/nuspojava. Također, u 
slučajevima mogućeg prijapizma izazvanog antipsihotikom, potrebno je razmotriti uvođenje lijeka s nižim 
antagonizmom za alfa-1 receptore i koristiti ga u najmanjoj učinkovitoj dozi. 
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Schizophrenia is a mental illness that can occur as 
early as adolescence or in young adulthood. The illness 
is characterised by distinctive psychopathology. Patients 
with schizophrenia are oriented towards their inner 
world where delusional events prevail, thus making 
them apathetic towards the reality they tend to isolate 
themselves from. Clinical manifestations of the illness, 
as well as its types can vary. However, in a 
psychopathological sense, their common features are 
thought and affective disorder and failure to function 
adequately. Human sexual function is complex and 
affected in many different ways by schizophrenia and 
the antipsychotic drugs used in its treatment. Sexual 
dysfunction is a common problem in people with 
schizophrenia, especially in men, with reported 
prevalence rates of 16.8% to 70%.1 The evaluation of 
the effects of antipsychotics on sexual function in 
patients with schizophrenia is also complex because 
the deleterious effects of conventional antipsychotics 
are superimposed on the effects of the disease itself.2 
Priapism is defined as a persistent, often painful penile 
erection not associated with sexual stimulation. 
Although relatively uncommon, priapism represents a 
urologic emergency because without prompt 
recognition and treatment it can result in urinary 
retention, cavernosa fibrosis, impotence, or even 
gangrene.3 Priapism as a medication side effect 
accounts for 25%-40% of all cases, with the most 
commonly associated categories of drugs being 
antipsychotics and antihypertensives.4 Atypical 
antipsychotics, also known as second-generation 
antipsychotics, owing to their favourable side effect 
profile, are the first line of treatment for schizophrenia. 
Second generation antipsychotics have their 
advantages in comparison to typical antipsychotics, but 
can also cause serious side effects including priapism.5 
Priapism is a rarely reported, underappreciated side 
effect which has been documented with nearly all       
the atypical antipsychotic medications including 
olanzapine.6,7 The mechanism of priapism associated 
with antipsychotics agents is thought to be related to 
alpha-adrenergic blocking properties. Detumescence is 
sympathetically mediated, and alpha1-adrenergic 
antagonism (within the corpora cavernosa) inhibits 
detumescence. The propensity of individual 
antipsychotics to induce priapism can presumably be 








A 54-year-old male patient has been receiving 
psychiatric treatment for 26 years. Mental illness was 
diagnosed in an outpatient clinic and confirmed while 
hospitalized at the age of 28. Having finished college, 
the patient has never been employed, lives with his 
parents, and his emotional relationships have been rare 
and short-lived. 
Following the last hospitalization 11 years ago, the 
patient regularly attended ambulatory psychiatric 
treatment and took his medications regularly. Over the 
past 4-5 years, the patient’s preoccupation with 
emotional (i.e. sexual) relationships which he couldn’t 
realize became apparent, and at times he expressed 
eroticised feelings. After 25 years of therapy with 
typical antipsychotics, tremor and akathisia were 
noticed as side effects of having been treated for years 
with fluphenazinum 5 mg, biperidenum 2 mg and 
clozapine 75 mg daily. The patient agreed the 
aforementioned psychopharmaca to be completely 
discontinued and for olanzapine to be introduced, with 
the dosage titrated to 7.5 mg, as well as diazepam 10 
mg daily. Eventually, stable remission was established. 
Seven years later, alcohol abuse was noticed, which 
caused the patient to be uncritical and lacking adequate 
insight. Over the course of three months, the patient 
was motivated into a group treatment, which he    
joined in. The psychosocial program consisted of 3 
components: 1) a psycho-education group led by a 
psychiatrist; 2) social skills training group lead by a 
trained nurse and a social worker and 3) therapeutic 
community where all members of the therapeutic team 
participated together. The weekly schedule consisted 
of one psychoeducational session, one social skills 
training and one session of the therapeutic community. 
Psychoeducation consisted of providing structured 
information on the illness and treatment, specifically 
about a) symptoms – how to recognise them, how to 
cope and what to do in case of deterioration; b) 
medication – information about pharmacotherapy, 
possible side effects and the importance of adherence; 
and c) how to improve general social functioning. 
Three months later, encouraged by the group, the 
patient mentioned painful penile erection, which he 
used as an excuse for his alcohol abuse. Olanzapine 
was gradually reduced in therapy and risperidone 
introduced by gradual titration (4 mg daily), taking into 
consideration the fact that risperidone can also have 
sexual side effects. Four weeks after having 









People with schizophrenia often experience some 
kind of sexual dysfunction, however, due to the 
complex nature of the disease and the wide range of 
side effects of antipsychotics making it difficult to 
determine their aetiology. In the described case, 
remission was maintained with olanzapine, but painful 
penile erection occurred, which gave no indication 
whether it was a side effect caused by olanzapine or 
psychopathology. Olanzapine was gradually replaced 
with risperidone and within four weeks the painful 
erection subsided completely. Many medications have 
been associated with priapism, which is thought to be 
related to alpha-adrenergic blockade. Detumescence is 
sympathetically mediated, and alpha-adrenergic 
antagonism (within the corpora cavernosa) inhibits 
detumescence. Olanzapine has a pharmacological 
profile similar to that of clozapine, with a high affinity 
for dopamine D1, D2, and D4, serotonin (5-HT) 5-
HT2A, 5-HT2C, and 5-HT3, muscarinic, alpha1-
adrenergic, and histamine H1 receptors. On the other 
hand, studies also suggest that risperidone and 
ziprasidone have the highest antagonism at alpha-1, 
and olanzapine has the lowest.8 Risk factors for the 
development of priapism include recent dose changes, 
recent medication changes, reinitiation of medication 
after periods of noncompliance, concomitant substance 
use, and/or the use of other medications which also 
cause priapism.6 Patients tend to find it difficult to 
speak about the sexual side effects, as was the case 
with our patient who took three months, along with 
alcohol abuse, to gain courage and verbalize the 
problem. Furthermore, the long-term patients in stable 
remission are perhaps not given adequate attention 
when it comes to all life segments and life quality, 
especially the quality of sexual life. This case illustrated 
the importance of psychosocial interventions as a 
complementary approach to the pharmacological 
treatment of schizophrenia. Proper patient education 
on side effects, as well as obtaining complete historical 
information on side effects from other medications, 
can help prevent recurrence. Also, group psycho-
therapy can encourage patients to talk about their sex 
life and sex related side effects in order to prevent 
serious consequences. From the pharmacological side, 
a medication with less alpha-1 antagonism should be 




Patients with schizophrenia can experience side 
effects which are easily observed and diagnosed. Some 
side effects, such as priapism, can be difficult to tell 
apart from psychopathology at times, as was the case 
with this patient. The choice of the antipsychotic was a 
risky one, especially given the well-known sexual side 
effects of risperidone. In this case, however, 
risperidone proved to be a good choice, as the painful 
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 U tiskanom primjerku časopisa Medica Jadertina 2021;51(1):59-67, u radu "Javnozdravstveni značaj 
novotvorina: incidencija, mortalitet i hospitalizacije u Zadarskoj županiji od 1998. do 2018. godine" autora Ana 
Balorda, Sara Bilić Knežević, Ljilja Balorda i Alan Medić pogrešno je tiskan tekst na Slici 3. 
 Umjesto "Umrli od zloćudnih novotvorina .. „ u gornjem dijelu Slike 3, na stranici 63 treba stajati 
tekst: "Novooboljeli od zloćudnih novotvorina (C00-C97) po spolu, stope na 100.000. Incidence, malignant 
neoplasms, according gender, rate per 100,000 inhabitants." 
 
 Uredništvo se ispričava autorima. 
 
